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EVIDENCE OF ELEVATED MUSCLE PROTEIN BREAKDOWN (MPB)
PRECEDES MINOR MUSCLE WASTING IN EARLY COLORECTAL CANCER
S.M. Nyasavajjala, C. Srinath, S. Liptrot, A. Selby, D. Rankin, P. Atherton,
K. Smith, J.P. Williams, J.N. Lund, R. Singh, M.J. Rennie. School of
Graduate Entry Medicine and Health, Derby, University of Nottingham
Background and Aims: Baracos group developed a useful method with
clinical CT images to investigate muscle wasting. We applied this tech-
nique to colorectal cancer patients, in a subset of whom we investigated
muscle metabolism.
Methods: We analysed CT images (psoas major, L-3; gluteus maximus,
coccyx) for patients with colorectal cancers (n ¼ 65,73  11y) and patients
who proved normal on investigation(n ¼ 56,71  11y). In a subset (n ¼
18,74  10y) of the cancer patients, we also characterized muscle metab-
olism by stable-tracer and molecular methods.
Results: In the healthy patients, psoas thickness was 30(28,31) mm
(median (95%CI)) and 31(26,30) mm in cancer patients. Normal gluteus
thickness was 30(31,36) mm; 29(32,38) mm in patients; normal psoas
cross sectional area (CSA) was 2873(2708,3299) mm2 and in patients was
3049(2561,4155) mm2. In metabolism subset, psoas thickness was 30(28,
35) mm, gluteus thickness was 36(32, 38) mm; psoas CSA was 2973(2442,
3074) mm2. Thus in patients with early colorectal cancer signiﬁcant
wasting could not be detected by comparison with age-matched controls.
However, the metabolic subset, despite only minor losses of leg muscle (2–
15 g/day), showed “anabolic resistance” of MPS (fed state: 0.030  0.003
vs. 0.071  0.003 %/h) with no evidence of elevated MPB.
Conclusion: Establishment of muscle metabolic dysfunction precedes
major sarcopenia in colorectal cancer.DICHLOROACETATE INDUCES APOPTOSIS AND CELL-CYCLE ARREST IN
COLORECTAL CANCER CELLS BUT NOT IN NON-CANCEROUS CELLS
B.M. Madhok 1, S. Yeluri 1, S.L. Perry 1, T.A. Hughes 2, D.G. Jayne 1. 1 Section of
Translational Anaesthesia and Surgery, University of Leeds; 2 The Leeds
Institute of Molecular Medicine, University of Leeds
Introduction: Cancer cells undergo increased glycolysis, the so-called
‘Warburg effect’. The aim of this study was to determine if switching
metabolism from glycolysis towards mitochondrial respiration would
preferentially induce apoptosis in colorectal cancer cells and examine the
underlying mechanisms.
Methods: Representative colorectal cancer and non-cancerous cell lines
were treated with Dichloroacetate, a non-speciﬁc inhibitor of pyruvate
dehydrogenase kinase (PDK), which promotes mitochondrial respiration.
Cellular proliferation, apoptosis, cell-cycle proﬁle, mitochondrial
membrane potential (Δjm), and glycolytic metabolism were measured.
Results: 20 mMDichloroacetate did not affect growth of non-cancerous 293
and HB2 cells, but caused signiﬁcant decrease in proliferation of all the cancer
cells; HT29, SW480, and LoVo (p ¼ 0.009), associated with a signiﬁcant
increase in apoptotic cells, and an eight-fold increase in number of cells in G2
phaseamongst cancercells suggesting inductionofG2arrest. The largesteffect
on apoptosis was seen in metastatic LoVo cells with 50 mM Dichloroacetate
resulting in a 21% (95% CI: 9 to 34) increase in the apoptotic fraction. Dichlor-
oacetate reduced lactate levels and decreased Δjm in cancer cells (p¼ 0.043).doi:10.1016/j.ijsu.2010.07.003Conclusions: Dichloroacetate induces apoptosis in colorectal cancer cells
via themitochondrial pathway. Further research investigating inhibition of
speciﬁc isoforms of PDK, known to be differentially upregulated in cancer,
is underway.
NEUTROPHIL-LYMPHOCYTE RATIO – AN INDEPENDENT PREDICTOR OF
SURVIVAL IN BREAST CANCER
A. Hakeem, M. West, E. Stefanidis, R. Hardy, L. Martin. Breast Unit, Aintree
University Hospital NHS Trust, Liverpool
Aims: Higher neutrophil-lymphocyte ratios (NLR) on pre-operative
bloods have been shown to be associated with worse survival after
resection of colorectal and other cancers. This study aimed to determine if
NLR can be used as an independent predictor of survival in breast cancer.
Methods: Retrospective review of curative resection for breast cancer
between Jan 2001–Dec 2003 was performed. Prognostic factors were
evaluated by univariate Kaplan–Meier models and multivariate Cox
regression model of survival to test for independence.
Results: 406 underwent resection. 361 had bloods done pre-operatively
and were included. 357 females and 4 males. Mean age 59.2 (29–95) years.
The median follow-up was 89 (72–108) months. 271 patients had NLR <3
and 90 had NLR >3. Percentage deaths for NLR <3 (n ¼ 57, 21.0%) and NLR
>3 (n¼ 34, 37.8%). Mean survival was 97.4 (94.7–100.3) months in patients
with NLR <3 versus 88.7 (82.1–95.3) months in those with NLR >3. On
multiple regression analysis, NLR remained a signiﬁcant prognostic indi-
cator, after adjusting for NPI (Nottingham Prognostic Index) and other
factors (P ¼ 0.0261, 95% CI ¼ 0.7463–0.9216). On Kaplan-Meier survival
analysis of the subsets of groups [Log-Rank (Mantel-Cox) Chi-Square–
6.211, degree of freedom–1, P ¼ 0.013).
Conclusions: Pre-operative NLR is an independent predictor of survival in
breast cancer in this series.131 I-MIBG, A NOVEL APPROACH IN NEUROBLASTOMA TREATMENT
A.I. Morgan 1, S. Ramzy 2, M. Shehawy 2. 1 Norfolk and Norwich University
Hospital; 2National Cancer Institute, Cairo University
Neuroblastoma is the commonest extra-cranial solid-tumour of peripheral
sympathetic NS in children and leading cause of cancer-related deaths in
childhood(1–4Y). Tumour-cells take up, store and secrete catecholamine
metabolites and express the norepinephrine transporter, making meta-
iodobenzylguanidine (MIBG)-an analogue of norepinephrine- an ideal
tumour-speciﬁc agent for imaging and therapy when labelled with 131I or
123I. This randomised controlled trial presents our experience in using
131I-MIBG upfront therapy in diagnosing and treating Neuroblastoma.
Thirty-four patients had their treatment up-fronted by 3–4 cycles of 131
I-MIBG every 21–28 days guided by haematological recovery (Group A)
followed by ﬁrst-line chemotherapy. Surgical intervention varied accord-
ing to response aiming at complete tumour-clearance. Follow-Up (24–60
Months) and results were compared to the control-group of 36 patients
who had their treatment after a diagnostic 131I-MIBG approach. Group-A
demonstrated an objective response to initial 131I-MIBG therapy of 44.10%,
while group-B missed this response, not only the overall OR. following
completion of three main lines of treatment was signiﬁcantly higher in the
